Emeryville, Ca., USA - August 3, 2009, Emeryville, Ca., USA - NovaBay Pharmaceuticals announced that Roy J. Wu has joined the company as senior vice president for business development.
Article continues below
Mr. Wu received his MBA in International Finance from the University of San Francisco, School of Business. He has been a member of the American Association of Pharmaceutical Scientist Planning Committee for Harmonization of Pharmaceutical Science Requirements, the New York Pharma Forum, the Japan Society of Northern California, the Healthcare Study Group (JETRO New York), the Regulatory Affairs Professional Society, and the Licensing Executive Society and Drug Information Association. Mr. Wu has been a frequent speaker at conferences including the Bay Bio Panel, Hepatitis C in Search of a Cure, Conducting Clinical Trials in Japan, Pacific Rim Biotech Conference and BIO. Mr. Wu brings to NovaBay more than 30 years of highly successful experience in the pharmaceutical industry with increasingly responsible management positions in global business development, licensing, international marketing, project management, clinical development, and Pacific sector regulatory and pharmaceutical development. Previously, Mr. Wu was vice president of business development at Genelabs Technologies Inc., where he was responsible for all business development and licensing activities, including search, evaluation, contract negotiations for all in- and out-license transactions as well as alliance management and assisting in corporate financing activities. Prior to Genelabs, Mr. Wu participated in the 1997 establishment of Kissei Pharma, the U.S. subsidiary of Kissei Pharmaceuticals Co. of Japan. Mr. Wu also was director of business development for Quintiles-BRI, a clinical research organization, after working for 16 years at Syntex Corporation. At Syntex, he held numerous positions with increasing responsibility, beginning as a chemist at the Syntex Research Institute of Pharmaceutical Sciences and culminating as director of R&D Program Planning and Management for the company's Japanese subsidi ■